Abstracts from the SCT 42nd annual meeting (2021)

This session will use examples from an mRNA-1273 phase 1 COVID-19 vaccine trial to explore reporting and operational considerations for vaccine trials in the pandemic setting. The session is composed of three talks from members of the Statistical and Data Coordinating Center for the mRNA-1273 phase 1 trial followed by two discussants and a question-and-answer session. The mRNA-1273 phase 1 trial evaluated the safety and immunogenicity of several doses of the mRNA- 1273 vaccine. Three age groups were enrolled (18-55, 56-70, and 71 years or older) and followed for safety and immunogenicity. At the time of this writing, subjects are completing Day 209. The results of this trial combined with the phase 2 trial were used to justify the 100 mg dose used in the phase 3 trial. The expectation is that all Day 209 follow-up will be completed and the results published by the time of the session in May 2021. The speakers and discussants will share knowledge gained from their roles and will address questions from the audience about the design and conduct of the trial as well as the process of reporting trial results. This session is highly relevant to the meeting theme and is expected to be of interest for a wide audience. Talk one will provide a brief background of the mRNA-1273 vaccine study platform and will highlight issues that arise at the start of the clinical trial process during an outbreak. Ava Manokian, Data Manager, will address considerations for adopting accelerated timelines and quickly getting a trial launched from concept to first subject enrollment. Talk two will focus on strategies for handling enrollment, data entry, and data cleaning during trials in outbreak settings. Semhal Selamawi, Data manager, will discuss how the changing COVID outbreaks, protocol changes to add dose levels and age cohorts, and the immediate need for clean data presented challenges to data management. Talk three will introduce the issues related to trial reporting. The pandemic setting raised difficult questions about disseminating the results of clinical trials. Kaitlyn Cross, Senior Biostatistician, will describe all the major reporting occurring during the trial and how the study group navigated the large numbers of reports required in a short time. Topics will also include different assays that are used and how they are handled. These three speakers will be followed by talks from two discussants who will provide additional perspectives on this vaccine study. Discussant one, Britta Flach, Director Advanced Clinical Testing, will provide a perspective on the challenges associated with running a lab, specimen receipt and analysis, and reporting results. Discussant two, Dr Mat Makowski, will discuss the challenges of working on this high-profile trial and how all the different pieces fit together from a logistics and analytical standpoint. Our expectation is that these talks will generate many questions;hence, the remainder of the session is devoted to a panel style question-and-answer session with the speakers and discussants.

are unique to the current situation. For some of the challenges the proposed solutions in our survey could relatively easy be translated into practice. Others need further conceptual and empirical research. Our findings together with the increasing body of literature on COVID-19 research ethics, and further stakeholder engagement should inform the development of hands-on guidance for researchers, funders, RECs, and further oversight bodies.

Background
In December 2019, an outbreak of the previously unknown coronavirus SARS-CoV-2 that likely occurred in Hubei Province in China drew the world's attention. Subsequently, the virus spread rapidly on a global scale and led the WHO to declare a pandemic emergency on 11 March 2020. With the sudden outbreak of the novel virus resulting in COVID-19 disease, the international biomedical research community aimed to better understand the virus and disease and engaged in the development of therapies, diagnostics and prevention measures. On 27 June 2020, the registry clinicaltrials.gov listed 2,341 clinical studies, of which 1,314 (56%) were classified as interventional studies, and 257 clinical trials on COVID-19 were listed in the EudraCT database of the European Medicines Agency (EMA). The true number of clinical studies is probably much higher because most health-related observational studies are not prospectively registered [1].
The rapidly growing number of studies of one disease at the same time raises concerns about research ethics and best practices. Can clinical research that is planned, funded, reviewed, conducted and published in a very short time fulfil the necessary requirements of effective, efficient, and ethical science? To support the research community in these unprecedented times, the WHO published the document "Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID-19 R&D" on 29 March 2020 [2], which refers to already existing recommendations for ethical research during pandemics and briefly summarizes important points. The "Guidance on the management of clinical trials during the COVID-19 pandemic" of the European Commission and the EMA outlines some specific recommendations, for example, on informed consent [3]. Expert papers point out ethically relevant risks and the potential damage caused by poorly planned and conducted research and stress the importance of adhering to scientific standards in times of crisis [4].
These extraordinary pandemic circumstances most likely also pose challenges for the research ethics committees (RECs) that are in charge of the assessment of COVID-19 studies. However, there is little information available on what challenges RECs currently face and how they deal with those challenges. To the knowledge of the authors, only one report exists that describes which types of modifications were necessary in 41 reviewed proposals and explanatory documents reviewed at one Chinese hospital [5].
The objective of this study was to broaden the understanding of current challenges in the work of RECs through a status quo analysis across all German RECs.

Methods
Sampling: The sample included 52 German RECs that participate in the assessment of clinical study proposals as required by German law and professional regulations and that are members of the umbrella organization "Association of Medical Ethics Committees in Germany" (AKEK: Arbeitskreis Medizinischer Ethik-Kommissionen). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint Questionnaire: To study the "qualitative spectrum of challenges and proposed solutions" in the most efficient way, we developed a questionnaire with three open questions. In addition, RECs were asked to indicate the number of interventional studies and non-interventional study proposals assessed until 21 April 2020. For further details, see the original questionnaire in the appendix.
Survey: The survey was conducted between 21 April 2020 and 30 April 2020. The questionnaire was sent by e-mail together with a cover letter from the AKEK office, and the responses were returned to the AKEK office. The anonymized questionnaires were forwarded to the involved investigators (AF, AS, and DS) of the QUEST Center for analysis.
Analysis: To extract, analyse, and synthesize the relevant information on the challenges and proposed solutions mentioned in the responses from the 22 RECs, thematic text analysis was performed independently by two researchers (AF, AS) using MaxQDA version 2020. First, the codes were grouped under one or more principles as described in an internationally established framework for clinical research ethics [6]. Second, response passages mentioning challenges and solutions were identified, and descriptive codes were applied. Third, the coding results were compared to identify potential differences in coding. However, only minor differences occurred, which were solved through discussion. Fourth, themes mentioned in one response were matched with those from another response to collate the various codes and cluster the findings into categories and subcategories of challenges and solutions. All researchers discussed and slightly modified the matrix for internal consistency and agreed on the final matrix.

Results
A questionnaire was sent to 52 RECs, of which 22 (42%) participated in the survey. According to information from the AKEK office, these 22 RECs together assessed 50% of the total 15,501 study proposals in Germany in 2017 and 53% of the total 17,182 study proposals in 2018.
The 22 RECs reported that they had assessed a total of 441 study proposals on COVID-19 as of 21 April 2020. These proposals included 229 proposals for interventional COVID-19 studies, of which 42 related to German drug law (AMG: Arzneimittelgesetz), one related to German medical device law (MPG: Medizinproduktgesetz) and 187 related to the German professional code for physicians (Berufsrecht). In addition, there were 212 proposals for non-interventional studies.
The qualitative responses from the 22 RECs on perceived challenges and proposed solutions were all grouped under one or more of seven principles of the employed research ethics framework: social value, scientific validity, informed consent, respect for participants, independent review, favourable risk-benefit analysis and fair participant selection. We did not identify any responses that could be grouped under the eigths principle collaborative partnership. The analysis reached thematic saturation at the framework level. Thematic saturation implies that no new principles or other overarching themes, but only further subcategories, could be generated. Table 1 presents all challenges and proposed solutions derived from the thematic text analysis. In the following, we explain selected topics that were addressed more frequently or with diverse viewpoints in narrative form.
With regard to scientific validity, some RECs complained about a lack of relevant information to assess the study validity or pointed to inadequate statistics. Comments also highlighted the partial lack of a clear rationale for "repurposing studies". Some RECs mentioned that it was apparent from the proposals that the applicants were under time pressure and that this pressure partly negatively affected the methodological quality of the submissions. The mentioned solutions to these challenges were diverse and in part contradictory. Some respondents tolerated a "pragmatic" assessment of the . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint submitted documents. Others preferred additional meetings to discuss challenging issues in-depth. The requirement of biometric advice before the submission COVID-19 applications was mentioned as a strategy to ensure an effective and efficient advisory process and enable applicants to plan their studies better.
On the topic of informed consent, the vulnerability of patients requiring intensive care and facing isolation as an infection control measure was highlighted as a particular challenge. The isolation of COVID-19 patients makes direct contact with caregivers/legal proxy decision makers difficult. Many study proposals aimed explicitly or implicitly to include patients who were unable to give or restricted from giving informed consent. In addition, the RECs seemed to be uncertain or insufficiently prepared with regard to guidance on alternative or modified consent formats. A further problem arose from the question of which groups of COVID-19 patients were to be classified as unable to give or restricted from giving consent and according to which criteria. Suggested solutions for the inclusion of persons unable to give informed consent were to collect consent by proxy and/or deferred consent. The importance of written consent was noted; however, the possibility of consent by telephone and the use of photographs of the original documents in isolation situations were proposed as solutions as well.
The social value principle was challenged by the conduct of several insufficiently coordinated and thematically difficult-to-distinguish COVID-19 studies in one hospital/region. REC members also highlighted a general lack of clear target actions in the planning of several register projects. The coordination of studies at the university level or at the national level was mentioned as a possible solution. Another suggestion was an explicit priority setting for research projects.
Many RECs reported intensive time pressure in the processing of COVID-19 proposals that we identified as a challenge for the independent review principle. Due to the lack of time, RECs reported difficulties in guaranteeing a high-quality assessment of all submitted proposals. In addition, RECs mentioned a strong demand of the applicants for a quick assessment. Logistical problems, such as working from the home office, would make things even more difficult. The solutions proposed included additional REC meetings, prioritized assessment of certain types of proposals and the use of online services for communication within the REC and with applicants. Some RECs mentioned the option to focus their assessments on proposals for which their institutions hosted the lead principal investigator and to fast-track multicentre proposals for which their institutions only served as a cooperating research facility.
The principle of the fair selection of study participants was challenged, for example, by the frequent inclusion of clinical staff in studies. Furthermore, RECs struggled with participant selection because the number of required study participants exceeded the number of available COVID-19 patients. It was unclear for RECs how to allocate patients across studies or how to determine and rank "priority studies". As a proposed solution for the protection of hospital staff, RECs recommended that the applicants provide statements "on the careful handling of particularly vulnerable hospital staff". No potential solutions were mentioned for the allocation/priority setting problem.
A favourable risk-benefit ratio was difficult to pursue due to insufficient knowledge about COVID-19 and its heterogenic and rapidly changing clinical picture. The problems arose especially in intervention studies. Above all, the benefits for the participating patients were difficult to assess. Regarding risk, for example, the use of non-therapeutic research procedures, such as increased frequency of blood sampling, was partly insufficiently justified. A solution to this problem could be to check whether residual blood from routine care could be used. No solutions were mentioned for the problem of the difficulty of assessing benefits. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint Finally, RECs reported various challenges with data management and data protection regarding the sensitive information of study participants, which we assigned to the principle of respect for study participants. Proposed solutions included more anonymization or pseudonymization of data and a limitation of the use of the data to COVID-19 specific research projects.

Discussion
In a national survey of all 52 German RECs from April 2020, we studied the number of assessed COVID-19 study proposals and the qualitative spectrum of associated challenges and proposed solutions. The 22 RECs reported that they assessed 441 COVID-19 study proposals (229 interventional and 212 non-interventional). The reported challenges and proposed solutions were grouped under eight research ethics principles [6].
In the following, we supplement the survey results described above with a more detailed interpretation and information on initiatives that have been started since April to directly address some of the challenges in the coming months.
Shortly after the survey was distributed, the German Ministry of Education and Research (Bundesministerium für Bildung und Forschung: BMBF) funded the National Research Network, which, under the direction of Charité-Universitätsmedizin Berlin, is working on various approaches to improve the efficiency and effectiveness of national research on COVID-19 [7]. This network has the potential to strengthen scientific validity by providing, for example, standardized data sets for COVID-19 projects, a national database and measures for the coordination and creation of quality standards in medical research on COVID-19. In addition to harmonization and coordination, expert contributions highlighted the importance of not lowering the bar regarding the scientific validity of individual COVID-19 studies [4].
Regarding informed consent for persons unable to give consent or with restricted ability to give consent, there are already various previous experiences and recommendations in the context of emergency and intensive care medicine on the topic [8][9][10]. To address this topic in a practiceoriented way for COVID-19 research, these recommendations should be further developed and specified for isolated patients, acknowledging several infection control measures. COVID-19-specific recommendations on the topic of deferred consent or the monitoring of consent processes ("consent monitor") might be of particular relevance [11,12].
There is little previous experience with forecasting the social value of individual clinical studies [13], especially with priority setting across clinical studies in a pandemic situation. The prioritization of research projects is usually addressed from a long-term perspective and focuses on the prioritization of whole research areas [14]. For short-term prioritization, it might be possible to agree on ethically relevant prioritization criteria such as "clinical relevance" and a "sufficiently high probability of success". While the general clinical relevance of various therapeutic approaches to COVID-19 might be determined relatively well, there are important challenges in clarifying the likelihood of their success. The error rate of early clinical research is generally very high [15], and there is a lack of robust concepts for identifying study projects with a particularly high probability of success.
The exploratory survey reported here has the following limitations. First, many responses focused on the areas of scientific validity and informed consent, which may be related to the fact that the questionnaire explicitly asked about challenges and solutions regarding "statistics/study quality", "informed consent", and "other issues". However, the broad spectrum of challenges and proposed solutions mentioned shows that many responding RECs expanded the focus. Second, we received a response rate of 42%. It is possible that the RECs that responded were the RECs where particular is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint challenges in connection with COVID-19 studies frequently arose. As described above, our survey did not aim to make a statement about the frequency of challenges but rather about the qualitative spectrum of the challenges described. Third, we could not verify the information on the number of applications processed.
Currently, there are many international contributions that address ethical issues in COVID-19 research, such as in "challenge studies" [16] or in "high-demand trials" [17]. Our status quo analysis on ethical issues based on feedback from 22 German RECs broadens our understanding of the spectrum of ethical challenges in COVID-19 research as perceived from those involved in the concrete review and oversight of COVID-19 studies. Further research on ethical challenges and proposed solutions as perceived by principle investigators and other stakeholder groups could complement this picture. Practice-oriented recommendations for the most pressing ethical challenges should be developed to support applicants, RECs, funders, potential research participants, and proxy decision makers in the best possible way ("pandemic response") and to prepare for future pandemic situations ("pandemic preparedness"). The BMBF-funded project "PRECOPE -Preparedness and Response for Ethical Challenges in Human Subject Research during COVID-19 and similar PandEmics", starting in August 2020, will address these tasks. Based on a systematic literature review, in-depth interviews, and further stakeholder engagement, PRECOPE aims to develop practice-oriented recommendations for the most pressing ethical challenges. As most ethical challenges in COVID-19 research ethics are expected to be on a global scale, international cooperation in developing preparedness and response measures is of utmost importance.
Declarations . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint • Requests from experts (e.g., for suggested biometrics) and additional REC meetings to discuss proposals in detail could be adopted. • Studies could be subdivided into one main study with the possibility of submitting (ethically more problematic) sub-studies via amendments. • If the essential aspects of the trial are evident from the proposal documents and there are no fundamental concerns, a positive vote with comments is given, indicating which aspects still must be supplemented in the study protocol. • Pragmatic assessment of initial proposal could be tolerated if an interim evaluation were planned.

Improvement of study planning and advisory process
• Documents could be prepared with the help of institutional . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint situation is constantly changing, leading to a necessity for a certain degree of extrapolation is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.11.20168773 doi: medRxiv preprint